Codexis Appoints Patrick Yang to Board of Directors
News Feb 28, 2014
Codexis, Inc. has announced the appointment of Patrick Yang, Ph.D., to its board of directors. Dr. Yang brings significant experience in pharmaceutical manufacturing and process development to the Codexis board, following several executive leadership roles within the pharmaceutical industry.
John Nicols, President and CEO of Codexis, said, "Dr. Yang's impressive track record in the pharmaceuticals industry, including leadership positions at Roche, Genentech and Merck, will bring valuable experience to our board. In addition to leveraging his extensive network in the global pharmaceutical industry, Codexis expects to greatly benefit from applying Dr. Yang's broad operational and technological expertise to help accelerate the profitable growth of our biocatalyst business going forward."
Dr. Yang commented, "I am excited to join the board of Codexis, particularly at this important stage in the company's history. The pharmaceutical market is the right focus for Codexis and its great technology, and now that Codexis is fully focused on this market, I can use my 35 years of experience in this industry to create value for both the company's shareholders and customers."
Dr. Yang served most recently as Executive Vice President and Global Head of Technical Operations for F. Hoffmann-La Roche AG, a world leader in research-focused pharmaceuticals and diagnostics.
In this role, Dr. Yang was responsible for Roche's pharmaceutical and biotech manufacturing operations, process development, quality, regulatory, supply management and distribution functions, and was accountable for more than 15,000 employees worldwide.
Previously, Dr. Yang worked for Genentech, a leading biotechnology company, for about 10 years, where his most recent position was Executive Vice President of Product Operations. At Genentech, Dr. Yang was responsible for Genentech's manufacturing, process development, quality, regulatory affairs and distribution functions.
Prior to Genentech, Dr. Yang held several leadership roles at Merck & Co., including Vice President of Asia/Pacific Manufacturing Operations and Vice President of, Supply Chain Management. He also previously worked at General Electric Co. and Life Systems, Inc. Dr. Yang serves on the board of directors of Tesoro Corporation (NYSE:TSO), an independent refiner and marketer of petroleum products.
Dr. Yang earned a Bachelor of Science in Engineering from the National Chiaotung University in Taiwan, a Master of Science in Electrical Engineering from the University of Cincinnati and a Ph.D. in engineering from the Ohio State University.
Arrow Poison Potential Male Birth ControlNews
Women have many options for oral contraceptives that are safe, effective and reversible, but despite decades of research, men have none. Now, scientists report a rat study that shows they finally have a good lead for a male birth control pill. It's based on ouabain, a plant extract that African warriors and hunters traditionally used as a heart-stopping poison on their arrows.READ MORE